MALAT1 and pancreatic neoplasm: A study showed that an elevated level of MALAT-1 decreased sensitivity to gemcitabine in pancreatic cancer cells [60], suggesting that down-regulation of MALAT-1 could increase the sensitivity of pancreatic cancer cells to gemcitabine.